Novel promoter and alternate transcription start site of the human serotonin reuptake transporter in intestinal mucosa

David R Linden, S. L. White, E. M. Brooks, G. M. Mawe

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Selective serotonin-reuptake inhibitors are therapies for psychological and bowel disorders, but produce adverse effects in the non-targeted system. To determine whether human serotonin-selective reuptake transporter (SERT) transcripts in the intestine are different from the brain, rapid amplification of cDNA ends, primer extension and RT-PCR assays were used to evaluate SERT transcripts from each region. Potential SLC6A4 gene promoter constructs were evaluated with a secreted alkaline phosphatase reporter assay. A novel transcript of the human SLC6A4 gene was discovered that predominates in the intestine, and differs from previous transcripts in the 5′-untranslated region. The distinct transcriptional start site and alternate promoter suggest that gastrointestinal SERT can be differentially regulated from brain SERT, may explain why the polymorphism in the previously identified promoter is associated with affective disorders, but not associated with gastrointestinal dysfunction, and suggest the intriguing possibility of the development of site-specific therapeutics for SERT regulation in the treatment of multiple disorders.

Original languageEnglish (US)
JournalNeurogastroenterology and Motility
Volume21
Issue number5
DOIs
StatePublished - May 2009
Externally publishedYes

Fingerprint

Serotonin Plasma Membrane Transport Proteins
Transcription Initiation Site
Intestinal Mucosa
Intestines
5' Untranslated Regions
Serotonin Uptake Inhibitors
Brain
Mood Disorders
Genes
Alkaline Phosphatase
Serotonin
Complementary DNA
Psychology
Polymerase Chain Reaction
Therapeutics

Keywords

  • 5-hydroxytryptamine
  • Enteric nervous system
  • Enterochromaffin cell
  • Serotonin-selective reuptake inhibitor
  • SLC6A4

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology
  • Endocrine and Autonomic Systems

Cite this

Novel promoter and alternate transcription start site of the human serotonin reuptake transporter in intestinal mucosa. / Linden, David R; White, S. L.; Brooks, E. M.; Mawe, G. M.

In: Neurogastroenterology and Motility, Vol. 21, No. 5, 05.2009.

Research output: Contribution to journalArticle

@article{f9d6c87e83c841408430e4ecaf4f11e8,
title = "Novel promoter and alternate transcription start site of the human serotonin reuptake transporter in intestinal mucosa",
abstract = "Selective serotonin-reuptake inhibitors are therapies for psychological and bowel disorders, but produce adverse effects in the non-targeted system. To determine whether human serotonin-selective reuptake transporter (SERT) transcripts in the intestine are different from the brain, rapid amplification of cDNA ends, primer extension and RT-PCR assays were used to evaluate SERT transcripts from each region. Potential SLC6A4 gene promoter constructs were evaluated with a secreted alkaline phosphatase reporter assay. A novel transcript of the human SLC6A4 gene was discovered that predominates in the intestine, and differs from previous transcripts in the 5′-untranslated region. The distinct transcriptional start site and alternate promoter suggest that gastrointestinal SERT can be differentially regulated from brain SERT, may explain why the polymorphism in the previously identified promoter is associated with affective disorders, but not associated with gastrointestinal dysfunction, and suggest the intriguing possibility of the development of site-specific therapeutics for SERT regulation in the treatment of multiple disorders.",
keywords = "5-hydroxytryptamine, Enteric nervous system, Enterochromaffin cell, Serotonin-selective reuptake inhibitor, SLC6A4",
author = "Linden, {David R} and White, {S. L.} and Brooks, {E. M.} and Mawe, {G. M.}",
year = "2009",
month = "5",
doi = "10.1111/j.1365-2982.2008.01247.x",
language = "English (US)",
volume = "21",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Novel promoter and alternate transcription start site of the human serotonin reuptake transporter in intestinal mucosa

AU - Linden, David R

AU - White, S. L.

AU - Brooks, E. M.

AU - Mawe, G. M.

PY - 2009/5

Y1 - 2009/5

N2 - Selective serotonin-reuptake inhibitors are therapies for psychological and bowel disorders, but produce adverse effects in the non-targeted system. To determine whether human serotonin-selective reuptake transporter (SERT) transcripts in the intestine are different from the brain, rapid amplification of cDNA ends, primer extension and RT-PCR assays were used to evaluate SERT transcripts from each region. Potential SLC6A4 gene promoter constructs were evaluated with a secreted alkaline phosphatase reporter assay. A novel transcript of the human SLC6A4 gene was discovered that predominates in the intestine, and differs from previous transcripts in the 5′-untranslated region. The distinct transcriptional start site and alternate promoter suggest that gastrointestinal SERT can be differentially regulated from brain SERT, may explain why the polymorphism in the previously identified promoter is associated with affective disorders, but not associated with gastrointestinal dysfunction, and suggest the intriguing possibility of the development of site-specific therapeutics for SERT regulation in the treatment of multiple disorders.

AB - Selective serotonin-reuptake inhibitors are therapies for psychological and bowel disorders, but produce adverse effects in the non-targeted system. To determine whether human serotonin-selective reuptake transporter (SERT) transcripts in the intestine are different from the brain, rapid amplification of cDNA ends, primer extension and RT-PCR assays were used to evaluate SERT transcripts from each region. Potential SLC6A4 gene promoter constructs were evaluated with a secreted alkaline phosphatase reporter assay. A novel transcript of the human SLC6A4 gene was discovered that predominates in the intestine, and differs from previous transcripts in the 5′-untranslated region. The distinct transcriptional start site and alternate promoter suggest that gastrointestinal SERT can be differentially regulated from brain SERT, may explain why the polymorphism in the previously identified promoter is associated with affective disorders, but not associated with gastrointestinal dysfunction, and suggest the intriguing possibility of the development of site-specific therapeutics for SERT regulation in the treatment of multiple disorders.

KW - 5-hydroxytryptamine

KW - Enteric nervous system

KW - Enterochromaffin cell

KW - Serotonin-selective reuptake inhibitor

KW - SLC6A4

UR - http://www.scopus.com/inward/record.url?scp=65349138887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349138887&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2982.2008.01247.x

DO - 10.1111/j.1365-2982.2008.01247.x

M3 - Article

C2 - 19222758

AN - SCOPUS:65349138887

VL - 21

JO - Neurogastroenterology and Motility

JF - Neurogastroenterology and Motility

SN - 1350-1925

IS - 5

ER -